Bcl-2 (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inhibiting (anti-apoptotic) or inducing (pro-apoptotic) apoptosis.
The symptoms of hematological malignancies are often mild or not apparent, which delays diagnosis and treatment. To overcome this challenge, many organizations such as KNOW AML group and market vendors have been organizing awareness campaigns, which educate patients about the symptoms and available diagnostic methods and treatment options. This factor has increased the sales of various therapeutics, including BCL-2 inhibitors, which is a crucial drug for treating indications such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and acute myeloid leukemia (AML). The awareness programs also conduct cancer screening and encourage people to become blood stem cell donors. This will provide significant growth opportunities to market vendors.
In 2018, the global B-cell lymphoma 2 Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global B-cell lymphoma 2 Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the B-cell lymphoma 2 Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
AbbVie Inc.
F. Hoffmann-La Roche Ltd.
Santa Cruz Biotechnology
Tocris
Biovision
...

Market segment by Type, the product can be split into
Combination Therapy
Monotherapy

Market segment by Application, split into
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Cute Myeloid Leukemia

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global B-cell lymphoma 2 Inhibitors status, future forecast, growth opportunity, key market and key players.
To present the B-cell lymphoma 2 Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of B-cell lymphoma 2 Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.